Ultragenyx Pharmaceutical Inc. CEO Emil Kakkis said his company seized "an opportune moment" to enter gene therapy via the cash counter-offer for Dimension Therapeutics Inc. at $5.50 per share, or about $138 million, stacking the proposal against last month's all-stock bid valued at around $110 million by Regenxbio Inc.